Novo Nordisk NVO is scheduled to report its third-quarter 2025 results before the opening bell on Nov. 5, 2025. The Zacks ...
Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...
Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...
Investor's Business Daily on MSN
Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge
Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock.
Shares of Hims & Hers Health ($HIMS) rallied in pre-market hours on Tuesday after management said it’s in discussions with ...
Novo Nordisk's new CEO, Mike Doustdar, is under significant pressure as the company contends with declining stock prices, ...
Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...
Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...
Novo Nordisk's board changes stem from disagreements with the Novo Nordisk Foundation over board composition and strategic ...
Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback